Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)
Status:
Terminated
Trial end date:
2018-11-28
Target enrollment:
Participant gender:
Summary
The main purpose for this study is to provide access to 3,4 DAP, a drug which has
demonstrated to be effective in treating weakness associated with Lambert-Eaton Myasthenic
Syndrome. LEMS is a rare autoimmune cause of a defect in neuromuscular transmission. The
disorder is clinically characterized by fluctuating muscle weakness, hyporeflexia and
autonomic dysfunction.
Phase:
Phase 2
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center Jeffrey A. Cohen, MD